T-Cell therapy Market Expected to Reach $15.2 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “T-Cell Therapy Market," The T-cell therapy market size was valued at $2.8 billion in 2022, and is estimated to reach $15.2 billion by 2032, growing at a CAGR of 18.3% from 2023 to 2032.

The major T-cell therapy market trends that drive the growth of the market are increase in prevalence of cancer, rise in geriatric population, and rise in adoption of various cell therapy technologies to manage the symptoms associated with cancer. The increasing prevalence of cancer, which includes conditions such as leukemia, myeloma, lymphoma, and relapse of cancer, results in demand for appropriate therapeutic treatment and thus drives the market growth. These conditions are often caused by genetic mutations or environmental factors, and T-cell therapy has shown promising results in treating them. 

Additionally, the geriatric population is at a higher risk of developing cancer compared to younger populations. According to the National Cancer Institute's report in 2021, more than 1,000 per 100,000 people in the age group of 60 years and older are at risk of cancer. This is because cancer is more likely to develop with age due to factors such as cellular damage, genetic mutations, and a weakened immune system. Thus, as the global population continues to age, the prevalence of cancer is expected to increase, which is further driving the growth during T-cell therapy market forecast. 

However, the factors that hinder the market growth are the strict government regulations on the approval of T-cell therapy. Furthermore, side effects of T-cell therapy and high cost of treatment also hamper the T-cell therapy market size. 

Moreover, the presence of favorable reimbursement policies is a significant driver of growth in the T-cell therapy market. According to the Federal Joint Committee (G-BA) in accordance with Section 91 SGB V, in April 2023, T-cell therapy was included as a reimbursable treatment option for certain types of cancer. Thus, such policies helped to increase patient access to T-cell therapy and contributed to the growth of the market. Furthermore, the technological advancements, rise in R&D activates and rise in approvals by regulatory agencies are offering lucrative opportunity for the key manufactures and growth T-cell therapy market analysis. 

On the basis of therapy type, the market is categorized into CAR T-cell Therapy and T Cell Receptor (TCR)-Based . The CAR T-Cell therapy segment occupied highest share in 2022 and is expected to remain dominant during the forecast period owing to exponential growth in number of CAR T-cell therapy clinical trial and growth in commitment of major key players in gene therapy.

However, T-cell receptor (TCR)- based segment is projected to register the highest CAGR during the forecast period, owing to its positive results in treatment of solid malignancies. Furthermore, the rise in focus of key players in expanding its application in treatment of different cancers such as melanoma is driving the growth. 

By indication, the market is categorized into Lymphoma, Acute Lymphocytic Leukemia,  and others (Multiple Myeloma, Melanoma). The Lymphoma segment occupied highest T-cell therapy market share in 2022 and is expected to remain dominant during the forecast period, owing to significant success of T-cell therapy in the treatment of blood cancers such as lymphoma. Additionally, the prevailing cases and ongoing research and development in this area are expected to drive the growth.

However, the others segment is projected to register the highest CAGR during the forecast period owing to growing interest in developing T-cell therapies for the treatment of such diseases, which are often more difficult to treat with traditional therapies. Additionally, recent advancements in T-cell therapy technology, such as TCR-based, have shown promising results in the treatment of Multiple Myeloma, Melanoma. 

Region wise, North America accounted for the largest T-cell therapy market share in terms of revenue in 2022. This growth is attributed to a rise in prevalence of cancer cases, growth in investment by private and public agencies and well-established research & commercialization base. In addition, the increase in the geriatric population in North America has led to a higher prevalence of cancer, leading to increased demand for ideal therapeutics. Moreover, the healthcare system has made significant investments in improving healthcare infrastructure and facilities, which has enabled better access to healthcare services and treatments for patients with cancer.

However, Asia-Pacific is expected to witness highest growth during the forecast period, owing to rising incidence of relapse cancer, increase in healthcare expenditure, growth in awareness about the importance of early detection and treatment of cancer and rise in adoption of gene therapy arena is expected to boost the market growth. 

Key findings of the study 
• On the basis of therapy type, the CAR T-cell therapy segment dominated the market in terms of revenue in 2022. 
• On the basis of indication, the Lymphoma segment dominated the T-cell therapy industry in terms of revenue in 2022. However, the others segment is anticipated to grow at the highest CAGR during the forecast period. 
• On the basis of end user, the hospitals segment dominated the T-cell therapy industry in terms of revenue in 2022. 
• Region wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.